Composition, medicine and health-care food for reducing blood pressure and preparation method of composition, medicine and health-care food

Abstract

The invention provides a composition, a medicine and a health-care food for reducing blood pressure and a preparation method, and belongs to the technical field of microorganisms. The invention provides a composition composed of probiotics as raw materials, and the probiotics in the composition can generate substances with an antihypertensive effect, such as short-chain fatty acid, gamma-aminobutyric acid and the like. In addition, by improving intestinal flora balance, reducing toxins generated by harmful bacteria and reducing inflammatory response, the composition has positive influence on blood pressure, influences cholesterol and triglyceride metabolism to a certain extent, and plays a role in regulating blood pressure. As a long-term health maintenance mode, the health of intestinal tracts and the stability of blood pressure can be favorably maintained. Eight strains in the composition have a synergistic effect, systolic pressure, average pressure and diastolic pressure can be remarkably reduced, and the composition can be used for preparing food, medicine or health care products for preventing and treating hypertension.

Description

Technical Field

[0001] The invention belongs to the technical field of microorganisms, and in particular relates to a blood pressure lowering composition, a medicine and a health food and a preparation method thereof. Background Art

[0002] Hypertension is currently the most widespread cardiovascular disease. Common symptoms include dizziness, headache, tight neck, fatigue, palpitations, etc., and may also cause shortness of breath, tinnitus, blurred vision, nosebleeds and other symptoms. Some patients are in a state of hypertension for a long time without obvious symptoms until serious complications occur. According to the World Health Organization, since 1990, the number of hypertensive patients aged 30 to 79 in the world has almost doubled, reaching 1.3 billion in 2019. By 2025, the number of hypertensive patients in the world is expected to reach 1.56 billion. Hypertension is the main cause of coronary heart disease, stroke, heart and kidney failure. Prevention and treatment of hypertension will help reduce the risk of cardiovascular diseases.

[0003] Common antihypertensive drugs include diuretics, beta-blockers, calcium channel blockers, angiotensin converting enzyme inhibitors (ACEI), angiotensin II receptor antagonists (ARB), etc. However, some antihypertensive drugs may cause patients to experience symptoms such as dizziness, fatigue, and dry cough, affecting their daily life and work; some drugs may cause side effects such as abnormal liver function and kidney damage. After the symptoms of hypertension occur, long-term medication is generally required to lower blood pressure, so the side effects need to be minimized. Summary of the invention

[0004] The present invention provides a blood pressure lowering composition, medicine and health food and a preparation method thereof. The composition has a blood pressure lowering function and can significantly reduce systolic blood pressure, mean blood pressure and diastolic blood pressure. It is safe and reliable, has no side effects and can be taken for a long time.

[0005] The invention provides a blood pressure lowering composition, comprising Lactobacillus plantarum LP-Onlly, Lactobacillus acidophilus LA11-Onlly, Bifidobacterium longum subspecies longum BL88-Onlly, Bifidobacterium animalis lactis subspecies BI516, Lactobacillus fermentum LF33, Lactobacillus salivarius LS86, Lactobacillus helveticus LH10 and Bifidobacterium breve BB8.

[0006] In a preferred embodiment of the present invention, the total number of viable bacteria in the blood pressure lowering composition is not less than 1.0×10 10 CFU / g.

[0007] In a preferred embodiment of the present invention, the following components are included in parts by weight: 5 to 15 parts of Lactobacillus plantarum LP-Onlly, 5 to 15 parts of Lactobacillus acidophilus LA11-Onlly, 5 to 15 parts of Bifidobacterium longum subspecies BL88-Onlly, 5 to 15 parts of Bifidobacterium animalis subspecies lactis BI516, 5 to 15 parts of Lactobacillus fermentum LF33, 5 to 15 parts of Lactobacillus salivarius LS86, 5 to 15 parts of Lactobacillus helveticus LH10 and 5 to 15 parts of Bifidobacterium breve BB8.

[0008] The present invention also provides a method for preparing the above-mentioned blood pressure lowering composition, comprising preparing Lactobacillus plantarum LP-Onlly, Lactobacillus acidophilus LA11-Onlly, Bifidobacterium longum subspecies longum BL88-Onlly, Bifidobacterium animalis lactis subspecies BI516, Lactobacillus fermentum LF33, Lactobacillus salivarius LS86, Lactobacillus helveticus LH10 and Bifidobacterium breve BB8 into freeze-dried powders respectively, mixing the freeze-dried powders to obtain the blood pressure lowering composition.

[0009] In a preferred embodiment of the present invention, the number of viable bacteria in each of the freeze-dried powders is not less than 3.0×10 11 CFU / g.

[0010] The present invention also provides the use of the blood pressure lowering composition in the preparation of blood pressure lowering drugs.

[0011] The present invention also provides a blood pressure lowering drug, comprising the blood pressure lowering composition and pharmaceutically acceptable excipients.

[0012] In a preferred embodiment of the present invention, it also comprises a medicinal raw material for lowering blood pressure.

[0013] The present invention also provides the use of the blood pressure lowering composition in preparing functional food that helps maintain a healthy blood pressure level.

[0014] The present invention also provides a functional food that helps maintain a healthy blood pressure level, comprising the blood pressure lowering composition and an edible carrier.

[0015] Beneficial effects: The present invention provides a composition composed of probiotics as raw materials, wherein the probiotics in the composition can produce substances with antihypertensive effects, such as short-chain fatty acids, γ-aminobutyric acid, etc. The composition of the present invention also improves the balance of intestinal flora, reduces toxins produced by harmful bacteria, reduces inflammatory reactions, thereby having a positive effect on blood pressure, and affects cholesterol and triglyceride metabolism to a certain extent, thereby regulating blood pressure. It can be used as a long-term health maintenance method to help maintain intestinal health and blood pressure stability.

[0016] In the composition of the present invention, the eight strains of bacteria act synergistically to significantly reduce systolic blood pressure, mean blood pressure and diastolic blood pressure, and can be used to prepare food, medicine or health care products for preventing and treating hypertension. DETAILED DESCRIPTION

[0017] The invention provides a blood pressure lowering composition, comprising Lactobacillus plantarum LP-Onlly, Lactobacillus acidophilus LA11-Onlly, Bifidobacterium longum subspecies longum BL88-Onlly, Bifidobacterium animalis lactis subspecies BI516, Lactobacillus fermentum LF33, Lactobacillus salivarius LS86, Lactobacillus helveticus LH10 and Bifidobacterium breve BB8.

[0018] In a preferred embodiment of the present invention, the total number of viable bacteria in the blood pressure lowering composition is not less than 1.0×10 10 CFU / g. The present invention does not have any special restrictions on the ratio of the probiotics in the composition. Generally, it is sufficient to meet the requirement of total viable bacteria count, and preferably the total viable lactic acid bacteria count is at least 3.0×10 11 CFU / gram requirement.

[0019] The blood pressure lowering composition of the present invention, in one embodiment, comprises 5 to 15 parts by weight of Lactobacillus plantarum LP-Onlly, such as 5 parts by weight, 6 parts by weight, 7 parts by weight, 8 parts by weight, 9 parts by weight, 10 parts by weight, 11 parts by weight, 12 parts by weight, 13 parts by weight, 14 parts by weight or 15 parts by weight.

[0020] In the blood pressure lowering composition of the present invention, in one embodiment, it includes 5 to 15 parts by weight of Lactobacillus acidophilus LA11-Onlly, such as 5 parts by weight, 6 parts by weight, 7 parts by weight, 8 parts by weight, 9 parts by weight, 10 parts by weight, 11 parts by weight, 12 parts by weight, 13 parts by weight, 14 parts by weight or 15 parts by weight.

[0021] In the antihypertensive composition of the present invention, in one embodiment, it includes 5 to 15 parts by weight of Bifidobacterium longum subspecies longum BL88-Onlly, such as 5 parts by weight, 6 parts by weight, 7 parts by weight, 8 parts by weight, 9 parts by weight, 10 parts by weight, 11 parts by weight, 12 parts by weight, 13 parts by weight, 14 parts by weight or 15 parts by weight.

[0022] The blood pressure lowering composition of the present invention comprises, in one embodiment, 5 to 15 parts by weight of Bifidobacterium animalis subsp. lactis BI516, such as 5 parts by weight, 6 parts by weight, 7 parts by weight, 8 parts by weight, 9 parts by weight, 10 parts by weight, 11 parts by weight, 12 parts by weight, 13 parts by weight, 14 parts by weight or 15 parts by weight.

[0023] In the antihypertensive composition of the present invention, in one embodiment, it includes 5 to 15 parts by weight of fermented mucus Lactobacillus LF33, such as 5 parts by weight, 6 parts by weight, 7 parts by weight, 8 parts by weight, 9 parts by weight, 10 parts by weight, 11 parts by weight, 12 parts by weight, 13 parts by weight, 14 parts by weight or 15 parts by weight.

[0024] In the blood pressure lowering composition of the present invention, in one embodiment, it includes 5 to 15 parts by weight of salivarius-associated Lactobacillus LS86, such as 5 parts by weight, 6 parts by weight, 7 parts by weight, 8 parts by weight, 9 parts by weight, 10 parts by weight, 11 parts by weight, 12 parts by weight, 13 parts by weight, 14 parts by weight or 15 parts by weight.

[0025] In the blood pressure lowering composition of the present invention, in one embodiment, it includes 5 to 15 parts by weight of Lactobacillus helveticus LH10, ​​such as 5 parts by weight, 6 parts by weight, 7 parts by weight, 8 parts by weight, 9 parts by weight, 10 parts by weight, 11 parts by weight, 12 parts by weight, 13 parts by weight, 14 parts by weight or 15 parts by weight.

[0026] In the blood pressure lowering composition of the present invention, in one embodiment, it includes 5 to 15 parts by weight of Bifidobacterium breve BB8, such as 5 parts by weight, 6 parts by weight, 7 parts by weight, 8 parts by weight, 9 parts by weight, 10 parts by weight, 11 parts by weight, 12 parts by weight, 13 parts by weight, 14 parts by weight or 15 parts by weight.

[0027] The plant lactobacillus LP-Onlly, Lactobacillus acidophilus LA11-Onlly, Bifidobacterium longum subspecies longum BL88-Onlly, Bifidobacterium animalis subspecies lactis BI516, Lactobacillus fermentum LF33, Lactobacillus salivarius LS86, Lactobacillus helveticus LH10 and Bifidobacterium breve BB8 described in the present invention have all been deposited in the General Microbiological Center of China National Committee for the Preservation and Administration of Microbiological Cultures, and the deposit numbers are CGMCC No.1258, CGMCC No.2106, CGMCC No.2107, CGMCC No.11959, CGMCC No.6407, CGMCC No.6403, CGMCC No.6404 and CGMCC No.6402, and has been disclosed in Chinese patents CN1644681A, CN101099749A, CN109432388A, CN116286468A and CN106234891A, so it will not be repeated here.

[0028] The probiotics of the present invention can produce proteases through metabolism, thereby degrading proteins, and producing angiotensin converting enzyme ACE activity inhibitory peptides, thereby playing a role in lowering blood pressure. The proteases produced by the probiotics of the present invention through metabolism include endopeptidase and aminopeptidase. Under the continuous action of these enzyme systems, biologically active peptides with different molecular sizes and effects are produced, thereby reducing the generation of angiotensin and lowering blood pressure. At the same time, probiotics can regulate metabolites, such as short-chain fatty acids, gamma-aminobutyric acid and other substances. Short-chain fatty acids can stimulate endothelial cells to produce nitric oxide synthase, thereby increasing nitric oxide, and nitric oxide is a vasodilator factor of traditional Chinese medicine, which relaxes vascular smooth muscle, dilates blood vessels, and lowers blood pressure. Gamma-aminobutyric acid can act on the vasomotor center of the spinal cord, effectively promotes the dilation of blood vessels, and achieves the purpose of lowering blood pressure. In addition, gamma-aminobutyric acid can also inhibit the secretion of antidiuretic hormone, effectively promote vasodilation, and lower blood pressure. The 8 bacterial strains in the present invention are all selected from the healthy human intestine, and can produce angiotensin converting enzyme ACE activity inhibitory peptides, short-chain fatty acids, γ-aminobutyric acid and other substances through metabolism, which can synergistically act with each other, thereby achieving the effect of lowering blood pressure.

[0029] The present invention also provides a method for preparing the above-mentioned blood pressure lowering composition, comprising preparing Lactobacillus plantarum LP-Onlly, Lactobacillus acidophilus LA11-Onlly, Bifidobacterium longum subspecies longum BL88-Onlly, Bifidobacterium animalis lactis subspecies BI516, Lactobacillus fermentum LF33, Lactobacillus salivarius LS86, Lactobacillus helveticus LH10 and Bifidobacterium breve BB8 into freeze-dried powders respectively, mixing the freeze-dried powders to obtain the blood pressure lowering composition.

[0030] In a preferred embodiment of the present invention, the number of viable bacteria in each of the freeze-dried powders is not less than 3.0×10 11 CFU / g. The present invention does not specifically limit the preparation method of the freeze-dried powder of the probiotics, and the probiotics can be prepared by conventional methods in the art, such as preparing freeze-dried powders of the raw bacteria separately in the embodiment, and then mixing the eight freeze-dried powders to prepare the probiotics.

[0031] In one embodiment of the present invention, the above eight probiotics are cultured and fermented in MRS culture medium or improved MRS culture medium to obtain fermentation liquid containing probiotics, and the above fermentation liquids are centrifuged to obtain bacterial mud, and the bacterial mud is mixed with water and a freeze-dried carrier in an amount of water that is 6 to 15 times the weight of the bacterial mud, and the obtained mixture is freeze-dried to prepare a freeze-dried powder. Wherein, the fermentation temperature is independently 37 to 39°C, such as 37°C, 37.5°C, 38°C and 39°C; the fermentation time is 12 to 30 hours, such as 12 hours, 13 hours, 14 hours, 15 hours, 16 hours, 17 hours, 18 hours, 20 hours, 21 hours, 22 hours, 23 hours, 24 hours, 25 hours, 26 hours, 27 hours, 28 hours, 29 hours or 30 hours. The number of viable bacteria in each fermentation liquid obtained by the present invention is greater than 2.0×10 9 CFU / ml, such as greater than 3 billion CFU / ml in the embodiment. The centrifugation described in the present invention can be performed in a 100,000-class clean workshop, and there is no special limitation on the centrifugation parameters. All centrifugation operations that can centrifuge and precipitate the live bacteria in the fermentation broth are within the protection scope of the present invention. When performing the freeze-drying, the present invention generally requires a freeze-drying carrier, and the freeze-drying carrier can be one or more of skimmed milk powder, trehalose, modified starch and maltodextrin. The present invention does not specifically limit the parameters of vacuum freeze-drying, and the vacuum freeze-drying method well known to those skilled in the art can be used.

[0032] The present invention also provides the use of the blood pressure lowering composition in the preparation of blood pressure lowering drugs.

[0033] In the embodiments of the present invention, animal experiments were conducted using the blood pressure lowering composition, and it was found that taking the blood pressure lowering composition for 7 to 14 days can significantly reduce systolic blood pressure; taking it for 21 to 28 days can significantly reduce systolic blood pressure, mean blood pressure and diastolic blood pressure.

[0034] The present invention also provides a blood pressure lowering drug, comprising the blood pressure lowering composition and pharmaceutically acceptable excipients.

[0035] The blood pressure lowering drug of the present invention can use the blood pressure lowering composition as the only active ingredient of the drug, or can be combined with other blood pressure lowering medicinal raw materials as a composite active ingredient. For example, in a preferred embodiment of the present invention, the blood pressure lowering medicinal raw material can be one or more of golden camellia, corn silk, mulberry leaf powder, eucommia leaf and kudzu root.

[0036] The drug of the present invention also includes a variety of pharmaceutical excipients added according to different dosage forms, wherein the dosage form can be powder, tablet, granule, liquid, pill, capsule or gel. When the preparation is prepared into different dosage forms, additives required for different preparations can also be added, such as wetting agents, disintegrants, dispersants, emulsifiers, etc., and those skilled in the art can add them appropriately according to the requirements of different dosage forms and prepare them using conventional preparation methods in the art. In the drug of the present invention, the total number of viable lactic acid bacteria can be 1.0 to 10×10 10 CFU / g, can also be 2.0~10×10 10 CFU / g, such as 2.0~5.0×10 10 CFU / g.

[0037] The present invention also provides the use of the blood pressure lowering composition in preparing functional food that helps maintain a healthy blood pressure level.

[0038] The present invention also provides a functional food that helps maintain a healthy blood pressure level, comprising the blood pressure lowering composition and an edible carrier.

[0039] The functional food of the present invention can also be compounded with Chinese medicines that are both edible and medicinal, such as one or more of golden camellia, corn silk, mulberry leaf powder, eucommia leaf and kudzu root. The functional food of the present invention also includes an edible carrier, which includes one or more of maltodextrin, oligosaccharides, water-soluble dietary fiber, sugar alcohol, starch, magnesium stearate and silicon dioxide. The total number of viable lactic acid bacteria in the functional food of the present invention is 1.0 to 10×10 10 CFU / g, can also be 2.0~10×10 10 CFU / g, the optimal range is 2.0~5.0×10 10 CFU / g.

[0040] The present invention has no particular limitation on the dosage form of the functional food, and the functional food may be in the form of powder, tablet, granule, liquid, pill, capsule or gel.

[0041] In order to further illustrate the present invention, a blood pressure lowering composition, medicine and health food and a preparation method provided by the present invention are described in detail below in conjunction with examples, but they should not be construed as limiting the scope of protection of the present invention.

[0042] Example 1

[0043] The following 8 probiotics were mixed to prepare a composition: 5 g of Lactobacillus plantarum LP-Onlly, 15 g of Lactobacillus acidophilus LA11-Onlly, 15 g of Bifidobacterium longum subspecies BL88-Onlly, 15 g of Bifidobacterium animalis subspecies BI516, 15 g of Lactobacillus fermentum LF33, 15 g of Lactobacillus salivarius LS86, 15 g of Lactobacillus helveticus LH10, ​​and 15 g of Bifidobacterium breve BB8. The total viable lactic acid bacteria count in the prepared composition was not less than 3.0×10 11 cfu / g.

[0044] Example 2

[0045] The following 8 probiotics were mixed to prepare a composition: 15 g of Lactobacillus plantarum LP-Onlly, 5 g of Lactobacillus acidophilus LA11-Onlly, 15 g of Bifidobacterium longum subspecies BL88-Onlly, 15 g of Bifidobacterium animalis subspecies BI516, 15 g of Lactobacillus fermentum LF33, 5 g of Lactobacillus salivarius LS86, 15 g of Lactobacillus helveticus LH10, ​​and 15 g of Bifidobacterium breve BB8. The total viable lactic acid bacteria count in the prepared composition was not less than 4.0×10 11 CFU / g.

[0046] Example 3

[0047] The following 8 probiotics were mixed to prepare a composition: Lactobacillus plantarum LP-Onlly 10g, Lactobacillus acidophilus LA11-Onlly 5g, Bifidobacterium longum subspecies longum BL88-Onlly 10g, Bifidobacterium animalis lactis subspecies BI516 15g, Lactobacillus fermentum LF33 15g, Lactobacillus salivarius LS86 15g, Lactobacillus helveticus LH10 15g and Bifidobacterium breve BB8 15g. The total viable lactic acid bacteria count in the prepared composition was not less than 5.0×10 11 CFU / g.

[0048] Example 4

[0049] 10 g of the probiotic composition prepared in Example 1, 10 g of xylo-oligosaccharide, 20 g of fructo-oligosaccharide, 20 g of litchi fruit powder, 30 g of erythritol and 10 g of maltodextrin were mixed to prepare probiotic powder. The total number of viable lactic acid bacteria in the product was not less than 3.0×10 10 CFU / g.

[0050] Example 5

[0051] 10 g of the probiotic composition prepared in Example 1 was mixed with 10 g of xylo-oligosaccharide, 20 g of fructo-oligosaccharide, 20 g of litchi fruit powder, 30 g of erythritol, 9 g of maltodextrin and 1 g of magnesium stearate, granulated and tableted. The total number of viable lactic acid bacteria in the product was not less than 3.0 × 10 10 CFU / g.

[0052] Example 6

[0053] 10 g of the probiotic composition prepared in Example 1 was mixed with 10 g of xylo-oligosaccharide, 20 g of fructo-oligosaccharide, 20 g of litchi fruit powder, 30 g of erythritol, 9 g of maltodextrin and 1 g of magnesium stearate, granulated and filled into capsules. The total number of viable lactic acid bacteria in the product was not less than 3.0 × 10 10 CFU / g.

[0054] Example 7

[0055] Example 4 Effect of the composition on hypertension model rats

[0056] The specific experimental plan is as follows:

[0057] Species & strain: SD rat Grade: SPF grade; Number and gender of animals purchased / transferred: 20, male; Number and gender of animals used: 20, male Weight: ≥200g; Rats were fed with 8% NaCl high-salt feed for 4 weeks, and when the blood pressure of the rats was ≥120mmHg, they were hypertensive rats. Blood pressure was measured once before administration, and then administration began, and the test oral solution was given by gavage once a day for 28 consecutive days. The blood pressure of the rats was measured on the 7th, 14th, 21st, and 28th days of administration, and the blood pressure of each rat was measured 5 times. The dosage is 30 times the human dose (6g / day), first prepared into a 0.3g / mL gavage solution, and then the combination is gavage-administered to rats for administration.

[0058] Detection indicators: ① Animal weight changes; ② Blood pressure: measure rat tail artery blood pressure. 20 rats, In-life duration: 5 days of adaptive feeding, 5 weeks of high-salt diet-induced hypertension model, 28 days of drug administration, a total of 68 days. Feeding temperature: 16-26℃ / 20-26℃ (daily temperature difference ≤4℃); Feeding humidity: relative humidity 30-70%. The allowable deviation of environmental temperature and humidity within the range specified in SOP is not considered as a deviation from the protocol.

[0059] Feeding and lighting: The light cycle is automatically controlled, with 12 hours of light and dark alternation every day, and the dark time can be interrupted intermittently due to the needs of research-related activities. The normal control group rats were fed with ordinary feed, and the model group and the drug treatment group were fed with 8% high-salt purified feed, and the experimental animals drank water (reverse osmosis water).

[0060] Experimental design:

[0061] Grouping: Divided into ① normal control group, ② hypertension model group, and ③ test substance treatment group, a total of 3 groups.

[0062] Table 1 Grouping and administration method

[0063] Grouping Number of animals Give medication Dosage Normal group 4 Normal diet No medication Model Group 8 High salt diet + saline Oral administration, 28 consecutive days Treatment Group 8 High-salt diet + solid beverages Oral administration, 28 consecutive days

[0064] Administration: Oral administration, once a day for 28 consecutive days.

[0065] Before administration, there was no significant difference in systolic, mean and diastolic blood pressure between the 8 rats in the model group and the 8 rats in the treatment group (no administration) (Table 2). After 7 and 14 days of administration, the systolic blood pressure of the rats in the treatment group began to decrease, which was significantly lower than that in the model group; but the degree of decrease in mean and diastolic blood pressure was not significant (Table 3 and Table 4); after 21 and 28 days of administration, the systolic, mean and diastolic blood pressure of the rats in the treatment group decreased significantly, which was significantly lower than that in the model group. The systolic blood pressure of the rats in the treatment group decreased most significantly compared with the model group (p<0.001), the mean blood pressure also decreased significantly (p<0.001), and the decrease in diastolic blood pressure also had a statistically significant difference (p<0.05) (Table 5 and Table 6). It can be seen that the composition of the present invention has a significant blood pressure lowering effect. Taking the composition for 7 to 14 days can significantly reduce systolic blood pressure; taking it for 21 to 28 days can significantly reduce systolic blood pressure, mean blood pressure and diastolic blood pressure.

[0066] Table 2 Body weight, heart rate and blood pressure of rats in each group before administration

[0067]

[0068] Table 3 Changes in body weight, heart rate and blood pressure of rats in each group after 7 days of drug administration

[0069]

[0070] Table 4 Changes in body weight, heart rate and blood pressure of rats in each group after 14 days of drug administration

[0071]

[0072]

[0073] Table 5 Changes in body weight, heart rate and blood pressure of rats in each group after 21 days of drug administration

[0074]

[0075]

[0076] Table 6 Changes in body weight, heart rate and blood pressure of rats in each group after 28 days of drug administration

[0077]

[0078]

[0079] Example 8

[0080] Example 4 Effect of the composition on improving blood lipids (cholesterol and triglycerides) in mice

[0081] The specific experimental plan is as follows:

[0082] Animals C57BL / 6 mice, SPF, male, weighing 18-20g. Administration route and volume, oral gavage, 10ml / kg. Drug preparation 0.5% carboxymethyl cellulose (CMCNa), weigh 5g carboxymethyl cellulose into 1000ml pure water, stir overnight. 3g / kg sample, accurately weigh 60g sample into 200ml 0.5% CMCNa, shake into a uniform brown suspension, store at 4℃, and prepare weekly. After the mice were adaptively fed, 5 mice were selected and given regular feed as the normal control group, and the remaining mice were induced with high-fat feed for 14 weeks. They were randomly divided into 2 groups (n=5) according to the total cholesterol level, and the treatment was given by gavage (po), once a day (qd), for 8 consecutive weeks. During the intervention period, the normal group was given regular feed, and the model and test group continued to be given high-fat feed, and four blood lipids were measured every 4 weeks.

[0083] Table 7 Grouping and drug administration design

[0084] Group Number of animals (n) Dosage and administration Normal group 5 - Model Group 5 Excipients, po×qd Test group 5 3g / kg, po×qd

[0085] The mice in the normal group, model group and test group were intervened in different ways for 8 weeks, and the changes in total cholesterol and triglycerides are shown in Tables 8 and 9. In Tables 8 and 9, vs. the model group, *p<0.05, **p<0.01. After 14 weeks of high-fat diet induction, the total cholesterol of the mice was significantly increased compared with the normal group. After 8 weeks of test intervention, compared with the model group, the total cholesterol in the test group decreased significantly (p<0.05); triglycerides decreased significantly (p<0.05). The composition prepared in Example 4 can improve total cholesterol and triglycerides to a certain extent.

[0086] Table 8 Changes in total cholesterol in high-fat mice after 8 weeks of intervention (Mean±SD)

[0087]

[0088]

[0089] Table 9 Changes in triglycerides after 8 weeks of intervention (Mean±SD)

[0090]

[0091] Although the above embodiment describes the present invention in detail, it is only a part of the embodiments of the present invention, not all of the embodiments. People can also obtain other embodiments based on this embodiment without creativity, and these embodiments all fall within the protection scope of the present invention.

Claims

1. A blood pressure lowering composition, characterized in that: Including Lactobacillus plantarum LP-Onlly, Lactobacillus acidophilus LA11-Onlly, Bifidobacterium longum subspecies longum BL88-Onlly, Bifidobacterium animalis subspecies lactis BI516, Lactobacillus fermentum LF33, Lactobacillus salivarius LS86, Lactobacillus helveticus LH10 and Bifidobacterium breve BB8.

2. The blood pressure lowering composition according to claim 1, characterized in that: The total number of viable bacteria in the blood pressure lowering composition is not less than 1.0×10 10 CFU / g.

3. The blood pressure lowering composition according to claim 1 or 2, characterized in that: The invention comprises the following components in parts by weight: 5 to 15 parts of Lactobacillus plantarum LP-Onlly, 5 to 15 parts of Lactobacillus acidophilus LA11-Onlly, 5 to 15 parts of Bifidobacterium longum subspecies BL88-Onlly, 5 to 15 parts of Bifidobacterium animalis subspecies BI516, 5 to 15 parts of Lactobacillus fermentum LF33, 5 to 15 parts of Lactobacillus salivarius LS86, 5 to 15 parts of Lactobacillus helveticus LH10 and 5 to 15 parts of Bifidobacterium breve BB8.

4. The method for preparing the blood pressure lowering composition according to any one of claims 1 to 3, characterized in that: The method comprises preparing plant lactobacillus LP-Onlly, Lactobacillus acidophilus LA11-Onlly, Bifidobacterium longum subspecies longum BL88-Onlly, Bifidobacterium animalis subspecies lactis BI516, Lactobacillus fermentum LF33, Lactobacillus salivarius LS86, Lactobacillus helveticus LH10 and Bifidobacterium breve BB8 into freeze-dried powders respectively, and mixing the freeze-dried powders to obtain the blood pressure lowering composition.

5. The preparation method according to claim 4, characterized in that: The number of viable bacteria in each freeze-dried powder is not less than 3.0×10 11 CFU / g.

6. Use of the blood pressure lowering composition according to any one of claims 1 to 3 in the preparation of blood pressure lowering drugs.

7. A blood pressure lowering drug, characterized in that: The invention comprises the blood pressure lowering composition according to any one of claims 1 to 3 and pharmaceutically acceptable excipients.

8. The blood pressure lowering drug according to claim 7, characterized in that: It also includes medicinal raw materials for lowering blood pressure.

9. Use of the blood pressure lowering composition according to any one of claims 1 to 3 in the preparation of functional foods that help maintain healthy blood pressure levels.

10. A functional food that helps maintain a healthy blood pressure level, characterized in that: The invention comprises the blood pressure lowering composition according to any one of claims 1 to 3 and an edible carrier.

Images